drugset / Trial / NCT06478875

Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism

NCT06478875

NaSingle-groupOpen-labelDiagnostic

Summary

PentixaFor radiolabeled with 68Gallium (68Ga) is a radiopharmaceutical targeting the CXC chemokine receptor 4 (CXCR4) receptor. The CXCR4 receptor is expressed in zona glomerulosa of the adrenal cortex and in aldosterone producing adenoma (APA). The objective of this study will be to evaluate in 25 patients if \[68Ga\]Ga-PentixaFor positron emission tomography (\[68Ga\]Ga-PTF-PET) imaging allows for the discrimination of patients with lateralized or non-lateralized secretion of aldosterone in adrenal glands classified based on adrenal vein sampling (AVS).

Timeline

Start
2024-06
Primary completion
2026-06
Completion
2027-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-Pentixafor Peptide 150 mbq Intravenous

Indications